0001415889-17-001001.txt : 20170615 0001415889-17-001001.hdr.sgml : 20170615 20170615131440 ACCESSION NUMBER: 0001415889-17-001001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170615 DATE AS OF CHANGE: 20170615 EFFECTIVENESS DATE: 20170615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AzurRx BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-288822 FILM NUMBER: 17912997 BUSINESS ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 BUSINESS PHONE: 646-699-7855 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 D 1 primary_doc.xml X0707 D LIVE 0001604191 AzurRx BioPharma, Inc. 760 Parkside Avenue Suite 304 Brooklyn NY NEW YORK 11226 646-699-7855 DELAWARE None BioPharma d'Azur, Inc. Corporation true 2014 Johan M. Spoor c/o AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Director Edward M. Borkowski c/o AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn NY NEW YORK 11226 Director Alastair M. Riddell c/o AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn NY NEW YORK 11226 Director Maged M. Shenouda c/o AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn NY NEW YORK 11226 Director Charles M. Casamento c/o AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn NY NEW YORK 11226 Director Biotechnology Decline to Disclose 06b false 2017-06-05 false true true false 0 Alexander Capital, LP 40077 None None 17 State Street 5th Floor New York NY NEW YORK 10004 CO COLORADO CT CONNECTICUT DE DELAWARE FL FLORIDA MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK RI RHODE ISLAND SC SOUTH CAROLINA TX TEXAS 5000000 5000000 0 false 0 27 311800 true 0 0 true Company requires short-term working capital to fund certain operating costs. AzurRx BioPharma, Inc. /s/ Johan M. Spoor Johan M. Spoor President and CEO 2017-06-15